Xbrane Biopharma: Ximluci Launched in Europe - Redeye

Redeye endorses today's press release announcing that Ximluci is now being launched by STADA and Xbrane in major European markets. This is a significant milestone as it marks Xbrane's first biosimilar launch and STADA's sixth, but the first in the ophthalmologic therapy area. Based on historical launches, biosimilars tend to quickly penetrate the originator's market, which should lead to a rapid sales ramp-up for Xbrane in 2023 and 2024. Updates on the resubmission of Ximluci's BLA to the FDA should also not be far off. Accordingly, we see exciting months ahead and reiterate our SEK173 base case, suggesting an ample upside opportunity.

Länk till analysen i sin helhet: https://www.redeye.se/research/892184/xbrane-biopharma-ximluci-launched-in-europe?utm_source=finwire&utm_medium=RSS